Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study of Cadonilimab(PD-1/CTLA-4 Bi-Specific Antibody) in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer

NCT06406673 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT06406673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06406673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study of Cadonilimab(PD-1/CTLA-4 Bi-Specific Antibody) in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
October 16, 2023
Completion date
December 31, 2024
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extensive small cell lung cancer